Abbreviations: Xeloda: capecitabine; AC: anthracycline and cyclophosphamide; VEGF mAb: vascular endothelial growth factor monoclonal Antibody; TBD: to be determined.
R&D
R&D Pipeline
Building balanced and differentiated pipeline covering products from early- to late-stage through both in-house development and in-licensing.
.
Assets
Indication
Combo
Development area
Pre-clinical
IND
Phase I
Phase II
Phase III
NDA
Commercial
Rights
Utidelone Injection
Advanced breast cancer
Xeloda
CN
GlobalXeloda
Global
GlobalAdvanced non-small cell lung cancer
Monotherapy
CN
GlobalMonotherapy
Global
GlobalBreast cancer neoadjuvant
AC
CN
GlobalPancreatic cancer
Chemo
CN
GlobalSolid tumors
Mono／PD-1
CN
GlobalBreast cancer brain metastasis
Xeloda
Global
GlobalLung cancer brain metastasis
VEGF mAb
CN
GlobalUtidelone Capsule
Solid tumors
Monotherapy
US
GlobalMonotherapy
CN
GlobalAdvanced breast cancer
Xeloda
CN
GlobalTNBC adjuvant intensive
Xeloda
CN
GlobalAdvanced gastric
Chemo ± PD-1
Global
GlobalAdvanced ovarian cancer
Mono ± VEGF mAb
Global
GlobalVEGF mAb
CN
GlobalUtidelone antibody-drug conjugate
Solid tumors
TBD
Global
GlobalBG22
Solid tumors
TBD
Global
GlobalBG18
Solid tumors
TBD
Global
GlobalBG44
Solid tumors
TBD
Global
Global